Anthony C Faber
机构: Virginia Commonwealth University
每年引用次数
引用次数
引用: 7,888
H-指数: 38
I10-指数 : 56
出版物: 123
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1 -amplified lung cancers with low FGFR1 protein expression
H Kotani , H Ebi , H Kitai , S Nanjo
Oncogene 35 ( 27) 3587 -3597
28
2016
Chemical targeting of AKT signaling including glycolysis in diffuse large B cell lymphoma
Anthony Charles Faber
Boston College
2007
Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma.
Cyril H Benes , Timothy L Lochmann , Patricia Greninger , Anthony C Faber
Proceedings of the National Academy of Sciences of the United States of America 118 ( 13)
2021
Venetoclax-based rational combinations are effective in models of MYCN-amplified neuroblastoma.
Yaël P Mossé , Cyril H Benes , Patricia Greninger , Renata Sano
Molecular Cancer Therapeutics
2021
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
S Michael Rothenberg , Kyle Concannon , Sarah Cullen , Gaylor Boulay
eLife 4
28
2015
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N Hata , Matthew J Niederst , Hannah L Archibald , Maria Gomez-Caraballo
Nature Medicine 22 ( 3) 262 -269
480
2016
Classification of gastrointestinal stromal tumor syndromes.
Priya Gopie , Lin Mei , Anthony C Faber , Steven R Grossman
Endocrine-related Cancer 25 ( 2)
15
2018
BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer.
Timothy L Lochmann , Ynes M Bouck , Anthony C Faber
Oncoscience 5 218 -219
16
2018
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
Sheeba Jacob , Tia H Turner , Jinyang Cai , Konstantinos V Floros
PNAS nexus 1 ( 5) pgac232
2022
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy
Valerie Carpenter , Tareq Saleh , So Min Lee , Graeme Murray
Biochemical Pharmacology 193 114765
9
2021
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Jinyang Cai , Sheeba Jacob , Richard Kurupi , Krista M Dalton
Cell reports 40 ( 4)
7
2022
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Anthony C Faber , Ryan B Corcoran , Hiromichi Ebi , Lecia V Sequist
Cancer discovery 1 ( 4) 352 -365
334
2011
A microenvironment secretome screen reveals FGF2 as a mediator of resistance to anti-estrogens and PI3K/mTOR pathway inhibitors in ER plus breast cancer
Kevin Shee , John W Hinds , Wei Yang , Riley A Hampsch
Cancer Research 78 ( 4)
1
2018
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways
Stephen Michael Rothenberg , Kyle Concannon , Sarah Cullen , Alexa B Turke
Cancer Research 74 ( 19_Supplement) 4773 -4773
2014
Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma.
Ryan B Corcoran , Stephen M Rothenberg , Aaron N Hata , Anthony C Faber
Cancer Research 73 ( 8_Supplement) 4568 -4568
2013
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
Konstantinos V Floros , Ayesha T Chawla , Mia O Johnson-Berro , Rishabh Khatri
Cell Stress 6 ( 2) 21 -21
11
2022
Pharmaceutical interference of the EWS-FLI1–driven transcriptome by cotargeting H3K27ac and RNA polymerase activity in Ewing sarcoma
Daniel AR Heisey , Sheeba Jacob , Timothy L Lochmann , Richard Kurupi
Molecular Cancer Therapeutics 20 ( 10) 1868 -1879
10
2021
Pharmacologic inhibition of SHP2 blocks both PI3K and MEK signaling in low-epiregulin HNSCC via GAB1
Richard Kurupi , Konstantinos V Floros , Sheeba Jacob , Ayesha T Chawla
Cancer research communications 2 ( 9) 1061 -1074
4
2022
Exploring the relationship between metabolism and the epigenome in MYCN-amplified neuroblastoma
Krista M Dalton , Timothy L Lochmann , Colin Coon , Marissa L Calbert
Cancer Research 84 ( 6_Supplement) 5119 -5119
2024
R9: A novel NuRD complex inhibitor for targeted therapy in triple negative breast cancer (TNBC)
Kun Zhang , Sheeba Jacob , Mikhail Dozmorov , Ivan Babic
Cancer Research 84 ( 6_Supplement) 5976 -5976
2024